Litcius/Paper detail

Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function

Farong Ye, Cheng Li, Feng‐Liang Liu, Xinliang Liu, Peng Xu, Rong‐Hua Luo, Wenping Song, Yong‐Tang Zheng, Tianlei Ying, Biao Yu, Ping Wang

2024National Science Review16 citationsDOIOpen Access PDF

Abstract

ABSTRACT Vaccines have been the primary remedy in the global fight against coronavirus disease 2019 (COVID-19). The receptor-binding domain (RBD) of the spike protein, a critical viral immunogen, is affected by the heterogeneity of its glycan structures and relatively low immunogenicity. Here, we describe a scalable synthetic platform that enables the precise synthesis of homogeneously glycosylated RBD, facilitating the elucidation of carbohydrate structure–function relationships. Five homogeneously glycosylated RBDs bearing biantennary glycans were prepared, three of which were conjugated to T-helper epitope (Tpep) from tetanus toxoid to improve their weak immune response. Relative to natural HEK293-derived RBD, synthetic RBDs with biantennary N-glycan elicited a higher level of neutralising antibodies against SARS-CoV-2 in mice. Furthermore, RBDs containing Tpep elicited significant immune responses in transgenic mice expressing human angiotensin-converting enzyme 2. Our collective data suggest that trimming the N-glycans and Tpep conjugation of RBD could potentially serve as an effective strategy for developing subunit vaccines providing efficient protection.

Topics & Concepts

GlycanImmunogenicityEpitopeImmune systemVirologyAntibodyBiologyGlycosylationHEK 293 cellsImmunogenChemistryComputational biologyReceptorImmunologyMolecular biologyGlycoproteinBiochemistryMonoclonal antibodyMonoclonal and Polyclonal Antibodies ResearchInfluenza Virus Research StudiesGlycosylation and Glycoproteins Research